Conflict of interest: NilAbstractAim: The current research aims to formulate and evaluated medicated transdermal patchescontaining an antidiabetic drug.Material & Methods: In the present study was conducted by the Department ofPharmacology, DMCH, Laheriasarai, Darbhanga, Bihar, India. An attempt has been made todevelop a matrix-type transdermal therapeutic system comprising of various PVP K30, MCratios and solvent evaporation techniques. A good penetration enhancer would improve drugdelivery from various polymer-based transdermal patches. Transdermal patches of the matrixtype are made. All prepared formulations were tested for weight variation, thickness, drugcontent, moisture content, moisture uptake, flatness, and in vitro drug release. Bath F3 wasoptimised formula from all formulation baths shows linear zero order release for 24 hours,with a cumulative percentage of drug diffusion of 87.35% from 4cm2 patches. It has beendetermined that polymer concentration.Results: The formulated films were examined for colour, clearness, softness and elasticity. Itwas précised by digital Vernier calipers. Three reading were taken for standard deviationafter thickness measured at five various site of patch. The thickness of Glimepiride patcheswere between112.48-124.26μm. The folding endurance of patches was found to besatisfactory between 121.49±2.36 to 128.42±0.46. This shows that patches would maintaintheir integrity and not break easily. The moisture content in the patches was ranged from 1.38± 0.26 to 2.80 ± 0.20% (for formulation F series and formulation respectively). The weightvariation of Glimepiride patches were in between 250 to 280 mg. This showed uniformity inweight of patches while the % drug content of Glimepiride in patches were between 96.00 to95.15±0.85% this shows passable drug content in patches.Conclusion: When the concentration of PVP K30 increases in the primary layer, the in –vitro diffusion rate increases, and when the concentration of PVP K30 decreases, the drugdiffusion decreases. It allows for more controlled drug release from the patch.

Conflict of interest: NilAbstractAim: The current research aims to formulate and evaluated medicated transdermal patchescontaining an antidiabetic drug.Material & Methods: In the present study was conducted by the Department ofPharmacology, DMCH, Laheriasarai, Darbhanga, Bihar, India. An attempt has been made todevelop a matrix-type transdermal therapeutic system comprising of various PVP K30, MCratios and solvent evaporation techniques. A good penetration enhancer would improve drugdelivery from various polymer-based transdermal patches. Transdermal patches of the matrixtype are made. All prepared formulations were tested for weight variation, thickness, drugcontent, moisture content, moisture uptake, flatness, and in vitro drug release. Bath F3 wasoptimised formula from all formulation baths shows linear zero order release for 24 hours,with a cumulative percentage of drug diffusion of 87.35% from 4cm2 patches. It has beendetermined that polymer concentration.Results: The formulated films were examined for colour, clearness, softness and elasticity. Itwas précised by digital Vernier calipers. Three reading were taken for standard deviationafter thickness measured at five various site of patch. The thickness of Glimepiride patcheswere between112.48-124.26μm. The folding endurance of patches was found to besatisfactory between 121.49±2.36 to 128.42±0.46. This shows that patches would maintaintheir integrity and not break easily. The moisture content in the patches was ranged from 1.38± 0.26 to 2.80 ± 0.20% (for formulation F series and formulation respectively). The weightvariation of Glimepiride patches were in between 250 to 280 mg. This showed uniformity inweight of patches while the % drug content of Glimepiride in patches were between 96.00 to95.15±0.85% this shows passable drug content in patches.Conclusion: When the concentration of PVP K30 increases in the primary layer, the in –vitro diffusion rate increases, and when the concentration of PVP K30 decreases, the drugdiffusion decreases. It allows for more controlled drug release from the patch.